🇺🇸 GILD — Gilead Sciences, Inc.
Salud CompraPrecio actual
166,89 USD
Máx. histórico
174,48
2 días
Split 2:1 del 28/01/2013
Caída desde máximo
-4,35%
Rango 52 semanas
116,88 – 176,58
Variación hoy
-0,41%
Cierre anterior
167,57
Rango de hoy
164,00 – 169,06
Volumen hoy
5.695.172
Peor caída histórica
-70,83%
27/01/1992 → 06/06/1994
Recuperado en 431 días
Volatilidad anualizada ⓘ
46,20%
- Nombre completo
- Gilead Sciences, Inc.
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - General
- Empleados
- 17.000
- PER ⓘ
- —
- Dividend yield
- 1,96% (puede no estar actualizado)
- Precio objetivo analistas
- 172,50 USD (puede no estar actualizado)
- Primera cotización
- 22/01/1992
- Precio actualizado
- hace 1 día
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Fecha de pago | Importe por participación |
|---|---|
| 15/09/2026 | 0,8200 USD |
| 15/06/2026 | 0,8200 USD |
| 13/03/2026 | 0,8200 USD |
| 15/12/2025 | 0,7900 USD |
| 15/09/2025 | 0,7900 USD |
| 13/06/2025 | 0,7900 USD |
| 14/03/2025 | 0,7900 USD |
| 13/12/2024 | 0,7700 USD |
| 13/09/2024 | 0,7700 USD |
| 14/06/2024 | 0,7700 USD |
| 14/03/2024 | 0,7700 USD |
| 14/12/2023 | 0,7500 USD |
| 14/09/2023 | 0,7500 USD |
| 14/06/2023 | 0,7500 USD |
| 14/03/2023 | 0,7500 USD |
| Fecha | Ratio |
|---|---|
| 28/01/2013 | 2:1 |
| 25/06/2007 | 2:1 |
| 07/09/2004 | 2:1 |
| 08/03/2002 | 2:1 |
| 22/02/2001 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/04/2013 | 47,91 | 48,35 | 47,56 | 47,74 | +0,23% | 1,65% | 10.050.300 |
| 03/04/2013 | 48,25 | 48,37 | 47,31 | 47,63 | -1,18% | 2,20% | 9.168.000 |
| 02/04/2013 | 48,33 | 48,38 | 47,97 | 48,20 | +0,46% | 0,85% | 15.536.500 |
| 01/04/2013 | 49,01 | 49,17 | 47,91 | 47,98 | -1,96% | 2,57% | 14.403.100 |
| 28/03/2013 | 47,86 | 49,48 | 47,85 | 48,94 | +2,56% | 3,41% | 18.502.100 |
| 27/03/2013 | 46,20 | 47,83 | 45,92 | 47,72 | +4,28% | 4,13% | 18.418.400 |
| 26/03/2013 | 45,15 | 45,89 | 45,11 | 45,76 | +1,73% | 1,73% | 7.122.900 |
| 25/03/2013 | 46,01 | 46,13 | 44,76 | 44,98 | -1,16% | 2,98% | 12.174.000 |
| 22/03/2013 | 45,13 | 45,56 | 44,84 | 45,51 | +2,18% | 1,60% | 8.290.600 |
| 21/03/2013 | 44,45 | 44,74 | 44,26 | 44,54 | +0,04% | 1,08% | 12.615.200 |
| 20/03/2013 | 44,81 | 44,82 | 44,29 | 44,52 | +0,32% | 1,18% | 7.041.300 |
| 19/03/2013 | 44,81 | 45,00 | 43,78 | 44,38 | -0,94% | 2,72% | 9.059.300 |
| 18/03/2013 | 44,74 | 45,01 | 44,10 | 44,80 | -0,82% | 2,03% | 9.084.200 |
| 15/03/2013 | 45,81 | 46,00 | 44,96 | 45,17 | -1,55% | 2,27% | 14.207.400 |
| 14/03/2013 | 45,90 | 46,14 | 45,68 | 45,88 | +0,02% | 1,00% | 8.979.700 |
| 13/03/2013 | 46,15 | 46,15 | 45,61 | 45,87 | -0,67% | 1,17% | 6.112.100 |
| 12/03/2013 | 45,97 | 46,37 | 45,53 | 46,18 | +0,52% | 1,83% | 9.915.900 |
| 11/03/2013 | 45,49 | 45,95 | 45,18 | 45,94 | +1,12% | 1,69% | 7.298.000 |
| 08/03/2013 | 45,24 | 45,55 | 44,51 | 45,43 | +1,07% | 2,30% | 6.885.100 |
| 07/03/2013 | 45,10 | 45,20 | 44,51 | 44,95 | -0,99% | 1,53% | 9.176.500 |
| 06/03/2013 | 45,23 | 45,45 | 44,64 | 45,40 | +0,84% | 1,79% | 8.542.200 |
| 05/03/2013 | 44,35 | 45,58 | 44,35 | 45,02 | +2,62% | 2,77% | 15.086.800 |
| 04/03/2013 | 43,53 | 43,88 | 43,18 | 43,87 | +0,97% | 1,61% | 8.814.000 |
| 01/03/2013 | 42,63 | 43,50 | 42,38 | 43,45 | +1,71% | 2,63% | 11.294.500 |
| 28/02/2013 | 43,03 | 43,18 | 42,71 | 42,72 | -0,40% | 1,09% | 10.104.200 |
| 27/02/2013 | 42,39 | 43,29 | 42,08 | 42,89 | +1,51% | 2,85% | 7.986.000 |
| 26/02/2013 | 42,14 | 42,42 | 41,69 | 42,25 | +0,38% | 1,73% | 7.196.000 |
| 25/02/2013 | 42,77 | 43,35 | 42,06 | 42,09 | -0,85% | 3,02% | 9.560.900 |
| 22/02/2013 | 41,66 | 42,49 | 41,60 | 42,45 | +2,19% | 2,14% | 6.138.700 |
| 21/02/2013 | 41,82 | 41,85 | 41,18 | 41,54 | -0,81% | 1,60% | 9.769.500 |